Figure 5.
Cellular immune responses elicited by modified vaccinia Ankara (MVA) prime/boost immunizations. Peripheral blood mononuclear cells (PBMCs) were obtained on days 0, 14, 28, 42, 56, 84, and 180 following MVA vaccination and tested by the interferon γ enzyme-linked immunosorbent spot assay against autologous MVA-infected (A) and Western Reserve vaccinia virus strain–infected (B) target cells. Data are presented as the median number of spot-forming cells per 106 effector PBMCs with interquartile ranges for each dose group, following subtraction of responses to medium alone. *P ≤ .02 for the 108 median tissue culture infective dose (TCID50) group vs the placebo group; **P ≤ .02 for the 107 TCID50 group vs the placebo group; ***P ≤ .04 for the 108 TCID50 group vs the 107 TCID50 group.